IDH1 has also been demonstrated as a therapeutic target; in a phase 1 study assessing the use of ivosidenib in IDH1-mutated AML, the rate of CR or CR with partial hematologic recovery was 30.4%, and the ORR was 41.6% [88]. This evidence concerns the gene IDH1 and acute myeloid leukemia.